[Pralidoxime for organophosphate poisoning: regarding two paediatric cases].
Bocanegra
M A
MA
Campanario
I
I
Moreno Perulero
M L
ML
Araujo
F
F
Encinas Barrios
C
C
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001285:Atropine / Q000627:therapeutic use; D019819:Budesonide / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002801:Cholinesterase Reactivators / Q000506:poisoning* / Q000627:therapeutic use*; D002802:Cholinesterases / Q000097:blood / Q000172:deficiency; D003128:Coma / Q000139:chemically induced / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage / Q000627:therapeutic use; D009268:Nalidixic Acid / Q000627:therapeutic use; D062025:Organophosphate Poisoning; D011041:Poisoning / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D011220:Pralidoxime Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D002801:Cholinesterase Reactivators; D011220:Pralidoxime Compounds; D009268:Nalidixic Acid; D019819:Budesonide; D001285:Atropine; D002802:Cholinesterases; D009241:Ipratropium; D008787:Metoclopramide; C028797:pralidoxime